P.01.18 a Real Life Observational Study on the Eradication of H. Pylori Infection in Patients Naïve to Treatment Using Concomitant Therapy or Bismuth Quadruple Therapy (Three-in-One Pill)

Gravina, Antonietta Gerarda; Nardone, Gerardo; Miranda, Alina; Sgambato, D.; Rocco, Alba; Visciola, Giulio; Tuccillo, Concetta; Compare, Debora; Dallio, Marcello; Granata, L.; Romano, Lorenzo; Luca, Giacomo De; Romito, Raffaele; Martorano, Marco; Mucherino, C.; Rocco, P.; Federico, Alessandro Di; Loguercio, C.; Romano, Marco

doi:10.1016/s1590-8658(18)30400-6

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, of the 57 relevant references initially identified, 30 studies met the inclusion criteria and were included in the systematic review and meta‐analysis (Figure ). During the full‐text review stage, the authors of five primary studies were contacted for data clarification.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Meta‐analysis of three‐in‐one single capsule bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori

2019

View full text Add to dashboard Cite

Background Bismuth‐containing quadruple therapy has been suggested as first‐line and rescue alternative for Helicobacter pylori eradication. Our objective was to perform a meta‐analysis evaluating the efficacy and safety of single capsule Pylera® (bismuth, metronidazole, and tetracycline) plus a proton‐pump inhibitor (PPI) in any line of treatment. Methods Studies were selected up to October 2018. Outcomes were eradication and adverse events (AEs) rates pooled using the generic inverse variance method. Results In total, 30 studies (6482 patients) were included in the systematic review. The intention‐to‐treat (ITT) efficacy was 90% (95% CI: 87%‐92%, 21 studies, I2 = 88%) in first‐line therapy, 89% (95% CI: 86%‐93%, 12 studies, I2 = 78%) in second‐line and 82% (95% CI: 78%‐87%, nine studies, I2 = 60%) in third‐line; with no differences by the type or dosage of PPI used. For metronidazole‐resistant infection, the ITT efficacy as first‐line therapy was 93% (95% CI: 90%‐96%, six studies, I2 = 0%). In second‐line therapies where patients had been previously treated with clarithromycin, the ITT efficacy was 90% (95% CI: 87%‐93%, 11 studies, I2 = 78%). The overall incidence of AEs was 43% (95% CI: 35%‐50%, 24 studies, I2 = 92%) and they were mostly mild. In nearly 3% of the cases, treatment was interrupted due to AEs. Conclusions A 10‐day treatment with Pylera® achieved an effective eradication rate of approximately 90% both in first‐ and second‐line therapy. This applies regardless of the type and dose of the PPI, in patients with clarithromycin‐ or metronidazole‐resistant strains, and in those previously treated with clarithromycin.

show abstract

Section: Resultsmentioning

confidence: 99%

“…In almost 3% of the cases, treatment was discontinued due to AEs. [16][17][18]27,[30][31][32]34,35,37,38,[42][43][44][45]47…”

Section: Safety Of Pylera ®mentioning

confidence: 99%

Meta‐analysis of three‐in‐one single capsule bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori

2019

View full text Add to dashboard Cite

show abstract

P.01.18 a Real Life Observational Study on the Eradication of H. Pylori Infection in Patients Naïve to Treatment Using Concomitant Therapy or Bismuth Quadruple Therapy (Three-in-One Pill)

Cited by 1 publication

References 0 publications

Meta‐analysis of three‐in‐one single capsule bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori

Meta‐analysis of three‐in‐one single capsule bismuth‐containing quadruple therapy for the eradication of Helicobacter pylori

Contact Info

Product

Resources

About